First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
Data Demonstrate Efficacy and Safety of KEYTRUDA 400 mg Every Six Weeks (Q6W) Comparable to Approved 200 mg Every Three Weeks (Q3W) Regimen
Resubmitted Supplemental Biologics License Applications (sBLAs) for KEYTRUDA Q6W Dosing Under Review with US FDA Across All Approved Adult Indications
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from Cohort B of KEYNOTE-555, a Phase 1 trial evaluating a 400 mg every six-week (Q6W) dosing regimen for KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with metastatic melanoma. Results of the study – which represent the first clinical outcomes evaluating Q6W dosing for KEYTRUDA – demonstrated efficacy and safety comparable to findings from previous melanoma trials evaluating KEYTRUDA monotherapy.
Media
Pamela Eisele
(267) 305-3558
Ayn Wisler
(908) 740-5590
Investors:
Peter Dannenbaum
(908) 740-1037
Raychel Kruper
(908) 740-2107
